Investigating Trends and Challenges in Prenatal Diagnosis of Monogenic Conditions in India—An LMIC Setting—Over Half a Decade
Prenatal Diagnosis · 2025
DOI: 10.1002/pd.6815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, 2025. Verfasst von Lois Sara James und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, Christian Medical College Vellore, Vellore, India. Hauptthemen laut MEDLINE: Prenatal Diagnosis, Genetic Diseases, Inborn, Genetic Testing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objectives
To study the overall trends, indications, timing, mode of testing, geographical distribution of cases and challenges in prenatal diagnosis (PND) of single gene conditions using invasive fetal testing in India over half a decade. We also studied the clinical indications of pregnant women undergoing targeted and expanded testing.
Methods
This is a retrospective analysis of data of pregnant women who underwent an invasive procedure for diagnosis of single gene conditions at a perinatal care center in South India between January 2018 and December 2022.
Results
Total 704 out of 1460 (48.2%) pregnant women underwent invasive testing for single gene conditions. Targeted testing was carried out in 636 cases (90.3%), while expanded testing comprised 68 cases (9.6%). The ratio of women undergoing targeted testing versus expanded testing was constant at 9:1 across the five years. While hemoglobinopathies ( n = 331, 47%) continued to be the most common indication for testing, other indications such as neurodevelopmental conditions ( n = 78, 11.1%) and inborn errors of metabolism ( n = 76, 10.8%) have shown a rising trend in the recent years ( p < 0.001). The number of women undergoing PND for single gene conditions has risen significantly across the study period ( p = 0.003). Over the years, there was also a significant rise in the use of whole exome sequencing ( n = 39, 57%) over clinical exome sequencing ( n = 27, 40%) ( p < 0.001).
Conclusions
Single gene conditions were major indications for prenatal invasive testing. Targeted testing was performed significantly more frequently than expanded testing. Although hemoglobinopathy continues to be the most common indication, others showed a rising trend in the recent years. For expanded testing, WES has been increasingly used over CES, especially in the recent years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Genetics, Christian Medical College Vellore, Vellore, India.
- Department of Hematology, Christian Medical College Vellore, Vellore, India.
- Fetal Medicine Unit, Department of OBGYN, Christian Medical College Vellore, Vellore, India.
- Department of Biostatistics, Christian Medical College Vellore, Vellore, India.
ORCID-Profile: Lois Sara James, Noel Deep Luke, Eunice Sindhuvi, Hemalatha Illangovan, Rekha Aaron, Preethi Raja Navaneethan, Mahasampath Gowri, Sumita Danda, Manisha Madhai Beck
Zitieren
APA
James, L. S., Luke, N. D., Sindhuvi, E., Illangovan, H., Aaron, R., Raja Navaneethan, P., Gowri, M., Danda, S., & Beck, M. M. (2025). Investigating Trends and Challenges in Prenatal Diagnosis of Monogenic Conditions in India—An LMIC Setting—Over Half a Decade. Prenatal Diagnosis. https://doi.org/10.1002/pd.6815
Vancouver
James LS, Luke ND, Sindhuvi E, Illangovan H, Aaron R, Raja Navaneethan P, et al. Investigating Trends and Challenges in Prenatal Diagnosis of Monogenic Conditions in India—An LMIC Setting—Over Half a Decade. Prenatal Diagnosis. 2025. doi:10.1002/pd.6815
BibTeX
@article{James2025,
author = {James, Lois Sara and Luke, Noel Deep and Sindhuvi, Eunice and Illangovan, Hemalatha and Aaron, Rekha and Raja Navaneethan, Preethi and Gowri, Mahasampath and Danda, Sumita and Beck, Manisha Madhai},
title = {Investigating Trends and Challenges in Prenatal Diagnosis of Monogenic Conditions in India—An LMIC Setting—Over Half a Decade},
journal = {Prenatal Diagnosis},
year = {2025},
doi = {10.1002/pd.6815}
}
EUVIMED